Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on Oct 21, 2022 4:04pm
150 Views
Post# 35039955

RE:RE:RE:RE:RE:RE:RE:Pfizer response to questions on M&A -> add value to company

RE:RE:RE:RE:RE:RE:RE:Pfizer response to questions on M&A -> add value to companyIn response to recent posts

-Simply Wall St is paid by its subscribers and recieves nothing from companies. It covers virtually every company on North American stock exchanges as well as Euorpean, Asian and others. It relies entirely on publicly available data. It is largely driven by algorythms that collect and analyze this data. It knows nothing about specific companies other than what is in their annual and quarterly reports. It does not contain or reflect on management commentary.

-Not everyone who questions  some aspect of a another poster's comments is a bunco artist or provecateur. 

-Going off on others weakens one's credibility. We all need credible comments here. It is tough out on this limb, waiting for mid-November. Let us all keep the faith.
<< Previous
Bullboard Posts
Next >>